Title of article
Treatment and outcome of intrahepatic cholangiocellular carcinoma
Author/Authors
Harald Puhalla، نويسنده , , Birgit Schuell، نويسنده , , Herwig Pokorny، نويسنده , , Gabriela Verena Kornek، نويسنده , , Werner Scheithauer، نويسنده , , Thomas Gruenberger، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
5
From page
173
To page
177
Abstract
Background
Treating intrahepatic cholangiocarcinoma (ihCCC) tumor resection leads to the best patient survival. The aim of this study was to investigate prognostic factors in resected patients.
Methods
This was a clinical observational series of 31 resected patients with ihCCC. Univariate analysis of clinical and pathologic factors in relation to patient survival and tumor recurrence were performed. Possible benefit of chemotherapy, although not given randomly, was investigated separately.
Results
The median follow-up time was 37.3 months. Of 31 resected patients a tumor-free resection (R0) was achieved in 26; 2 patients died postoperatively. Chemotherapy was administered to 19 patients. Overall survival was significantly better in patients with R0 resection, negative lymph nodes, a solitary tumor, and a width of resection margin greater than 3 mm. Recurrence-free survival was prolonged in patients with negative lymph nodes, early International Union Against Cancer (UICC) stages and solitary tumors. In UICC stages III and IV, patients receiving chemotherapy experienced a better overall survival.
Conclusions
Impact of various parameters on recurrence-free and overall survival was identified; a possible beneficial effect of adjuvant chemotherapy in advanced tumor stages was observed. A prospective, randomized trial is necessary to fully evaluate the role of adjuvant therapy.
Keywords
Cholangiocarcinoma , resection , chemotherapy , survival , Tumor-free survival
Journal title
The American Journal of Surgery
Serial Year
2005
Journal title
The American Journal of Surgery
Record number
617834
Link To Document